Germline Testing for Predisposition to Myeloid Malignancies
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChristopher Reilly
About this trial
The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.
Eligibility criteria
Qualifiers
Age of 18 years or older
Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
Ability to understand and provide a signed and completed consent document in English.
Disqualifiers
Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.
Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies
Trial design
Treatments tested in this trial
- MyeloGen Gene Panel
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Christopher Reilly
Lead sponsor
Dana-Farber Cancer Institute
Sponsor institution
Broad Institute of MIT and Harvard
Collaborator
Source ClinicalTrials.gov